Search for: "Watson Laboratories Inc" Results 121 - 140 of 143
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Mar 2014, 7:02 pm by FDABlog HPM
(“Allergan”) recently filed a Complaint against Watson Laboratories and Actavis Pharma alleging premature notice concerning generic RESTASIS (cyclosporine ophthalmic emulsion) 0.05%. [read post]
11 Apr 2016, 2:32 pm by Robert Reznick
  The FTC’s complaint attacks two such settlements that Endo Pharmaceuticals Inc. and the Japan-based patent holder for one of the relevant patents reached with generic manufacturers Watson Laboratories (and Watson’s current owner, Allergan plc) and Impax Laboratories, to settle Hatch-Waxman litigation involving Endo’s two most important products—the pain relievers Opana ER® and Lidoderm®.[2]  The FTC’s… [read post]
5 May 2014, 8:28 am by Gene Quinn
This prompted an Actavis subsidiary, Watson Laboratories, Inc., to file suit against the U.S. [read post]
8 Feb 2017, 3:09 am by Dennis Crouch
Watson Laboratories, Inc., No. 16-493 (pre-AIA, do secret sales count as prior art?) [read post]
16 Jan 2017, 5:44 pm by Dennis Crouch
Watson Laboratories, Inc., No. 16-493 (pre-AIA, do secret sales count as prior art?) [read post]
1 Apr 2018, 8:25 pm by Aaron Barkoff
Watson Laboratories Inc., 875 F.3d 636, for the proposition that the marketing of a generic drug with labeling that encourages infringement can be viewed as causing infringement despite the fact that the innovator company published the results of clinical studies and promoted the patented use. [read post]
10 Jul 2019, 5:45 am by Jennifer Brand
  Congratulations to the following Fastcase 50 award recipients:   Anette Aav, Director, IT Law Programme, University of Tartu Charlotte Alexander, Director, Legal Analytics Lab; Associate Professor, Georgia State University Jason Barnwell, Assistant General Counsel, Microsoft Raymond Bayley, CEO and Co-Founder, Novus Law LLC Kim Bennett, Founder, K Bennett Law Jess Birken, Founder, Birken Law Office Michael Bommarito, CEO and Co-Founder, LexPredict; Adjunct Professor of Law, Michigan… [read post]
1 Apr 2018, 8:25 pm by Aaron Barkoff
Watson Laboratories Inc., 875 F.3d 636, for the proposition that the marketing of a generic drug with labeling that encourages infringement can be viewed as causing infringement despite the fact that the innovator company published the results of clinical studies and promoted the patented use. [read post]
10 Oct 2016, 4:00 am by Karim Benyekhlef and Nicolas Vermeys
We are reminded of the wise words written by Justice Mahoney in Apple Computer, Inc. v. [read post]
20 Sep 2007, 12:02 pm
In re Watson, 517 F.2d 465, 472 & n.2 (Cust. [read post]